Sipai Health Technology (0314) investor relations material

Executive summary

• H1 2026 revenue fell 39.6% YoY to RMB739.9m as specialty pharmacy and Hui Min Insurance were scaled back; strategic focus shifted toward higher-margin insurance and physician research services.

• IFRS net profit was RMB42.9m versus a loss of RMB81.1m; normalized net profit was RMB6.9m versus a loss of RMB12.0m. IFRS profit included a RMB43.9m subsidiary-disposal gain.

• Gross margin rose 5.7 percentage points to 20.1%, while operating cash outflow narrowed to RMB26.6m from RMB63.5m.

Financial highlights

• Revenue was RMB739.9m, down 39.6% YoY; gross profit was RMB148.5m, down 15.7%.

• Operating profit was RMB0.2m versus a RMB60.4m loss; profit before tax was RMB43.6m versus an RMB82.4m loss.

• IFRS net profit was RMB42.9m versus a loss of RMB81.1m; normalized net profit was RMB6.9m versus a loss of RMB12.0m.

• Adjusted profit before normalization items was RMB51.1m; basic and diluted EPS were RMB0.07 versus RMB(0.12).

• Selling and marketing expenses fell 38.6% to RMB49.7m, administrative expenses fell 37.8% to RMB93.6m, and R&D expense rose 0.7% to RMB5.1m.

Outlook and guidance

• H2 priorities include expanding core businesses, improving operating cash flow and building sustainable profitable growth; no numerical guidance was stated.

• Investment focus includes corporate insurance, corporate healthcare management, life sciences insurance, reinsurance, specialist talent and digital platforms, with prudent financial discipline.

• Growth strategy combines organic expansion, specialist hiring and strategic acquisitions; pharmacy services are moving to a lower-asset network model supporting insurance and health management.